The Phosphate Binder Equivalent Dose

Seminars in Dialysis

Volumn 24, Issue 1, 2011, Pages 41-49

  Daugirdas, John T ^a   Finn, William F ^b   Emmett, Michael ^c   Chertow, Glenn M ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; PHOSPHATE;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; HUMAN; RENAL REPLACEMENT THERAPY;

CHELATING AGENTS; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS; RENAL DIALYSIS;

EID: 79951799417     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00849.x     Document Type: Article

References (44)

1. Suri RS, Garg AX, Chertow GM, et al. and the Frequent Hemodialysis Network Trial Group: Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int 71:349-359, 2007
2. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS: Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 83:66-73, 1989
3. Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS: Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 320:1110-1113, 1989
4. Ramirez JA, Emmett M, White MG, Fathi N, Santa Ana CA, Morawski SG, Fordtran JS: The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 30:753-759, 1986
5. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690-695, 1989
6. Pratt R, Martin P, Poole L, Dragone J: Reduction of dietary phosphorus absorption with lanthanum carbonate or sevelamer carbonate: a balance study. Am J Kidney Dis 55:4, 2010 (abstract)
7. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE: The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72:1255-1261, 2007
8. Heinrich T, Heidt H, Hafner V, Schmidt-Gayk H, Jenetzky E, Walter-Sack I, Mikus G, Bommer J: Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. Nephrol Dial Transplant 23:2861-2867, 2008
9. Burke SK, Slatopolsky EA, Goldberg DI: Sevelamer, a novel calcium and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 12:1640-1644, 1997
10. Russo D, Corrao S, Miranda I, Ruocco C, Manzi S, Elefante R, Brancaccio D, Cozzolino M, Biondi ML, Andreucci VE: Progression of coronary artery calcification in predialysis patients. Am J Nephrol 27:152-158, 2007
11. Sprague SM, Abboud H, Qui P, Dauphin M, Zhang P, Finn W: Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 4:178-185, 2009
12. Finn W, Kingma-Johnson I: Urinary phosphorus excretion is a valuable measure of total body phosphorus burden in patients with CKD stages 3 and 4. J Am Soc Nephrol 19:320A, 2008 (abstract TH-PO031)
13. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF: Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 54:619-637, 2009
14. d'Almeida Filho EJ, da Cruz EA, Hoette M, Ruzany F, Keen LN, Lugon JR: Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients. Sao Paulo Med J 118:179-184, 2000
15. Almirall J, Veciana L, Llibre J: Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. Am J Nephrol 14:192-196, 1994
16. Wallot M, Bonzel KE, Winter A, Geörger B, Lettgen B, Bald M: Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 10:625-630, 1996
17. Naghibi M, Nazemian F, Rajabi O, Hami M: Comparison of phosphate lowering properties of calcium acetate and calcium carbonate in hemodialysis patients. Iran J Pharmacol Therapeutics 5:73-76, 2006
18. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701, 1999
19. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
20. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914-1926, 2004
21. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M, CARE-2 Investigators: A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51:952-965, 2008
22. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72:1130-1137, 2007
23. Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S: Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 24:278-285, 2009
24. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH, Sevelamer Study Group: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19:405-412, 2008
25. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer HH, Raggi P, Bommer J: Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 20:1653-1661, 2005
26. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A: Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 100:c8-c19, 2005
27. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 63:S73-S78, 2003
28. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R: Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 72:252-258, 2009
29. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E: Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 49:163-167, 1996
30. Spiegel DM, Farmer B, Smits G, Chonchol M: Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr 17:416-422, 2007
31. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J: Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 25:3707-3717, 2010
32. Cam JM, Luck VA, Eastwood JB, DeWardener HE: The effect of aluminum hydroxide orally on calcium, phosphorus and aluminum metabolism in normal subjects. Clin Sci Mol Med 51:407-414, 1976
33. Spencer H, Kramer L, Norris C, Osis D: Effect of small doses of aluminum-containing antacids on calcium and phosphorus metabolism. Am J Clin Nutr 36:32-40, 1982
34. Clarkson EM, Luck VA, Hynson WV, Bailey RR, Eastwood JB, Woodhead JS, Clements VR, O'Riordan JLH, DeWardener HE: The effect of aluminum hydroxide on calcium, phosphorus and aluminum balances, the serum parathyroid hormone concentration and the aluminum content on bone in patients with chronic renal failure. Clin Sci 43:519-531, 1972
35. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986
36. National Kidney Foundation: K/DOQI Guidelines on bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl. 3):1-201, 2003
37. National Kidney Foundation: K/DOQI Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 35(Suppl. 2):S17-S104, 2000
38. Rufino M, de Bonis E, Martin M, Rebollo S, Martín B, Miquel R, Cobo M, Hernández D, Torres A, Lorenzo V: Is it possible to control hyperphosphatemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 13(Suppl. 3):65-67, 1998
39. Boaz M, Smetans S: Regression equation predicts dietary phosphorus intake from estimate of dietary protein intake. J Am Diet Assoc 96:1268-1270, 1996
40. Finn WF: Phosphorus management in end-stage renal disease. Semin Dial 18:8-12, 2005
41. Penne EL, van der Weerd NC, Grooteman MP, Mazairac AH, van den Dorpel MA, Nubé MJ, Bots ML, Lévesque R, Ter Wee PM, Blankestijn PJ, on behalf of the CONTRAST investigators: Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol in press
42. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S: Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 16:2778-2788, 2005
43. Lornoy W, De Meester J, Becaus I, Billiouw JM, Van Malderen PA, Van Pottelberge M: Impact of convective flow on phosphorus removal in maintenance hemodialysis patients. J Ren Nutr 16:47-53, 2006
44. Noori N, Sims JJ, Kopple JD, Shah A, Colman S, Shinaberger CS, Bross R, Mehrotra R, Kovesdy CP, Kalantar-Zadeh K: Organic and inorganic dietary phosphorus and its management in chronic kidney disease. Iran J Kidney Dis 4:89-100, 2010